Arjun Balar

Company: Loxo Oncology

Job title: Vice President - Global Clinical Development

Seminars:

Revealing Program Updates from LY3537982, a Highly Selective & Potent KRAS G12C Inhibitor 9:30 am

Discussing the discovery and rational design of LY3537982 its transition from bench to clinic Reviewing recent first-in-human data for LY3537982 in patients with KRAS G12C-Mutant Advanced Solid Tumors, Including NSCLC and CRC Exploring LY3537982 development avenues and promising future directionsRead more

day: Conference Day Two